Celldex Therapeutics (CLDX) vs Oruka Therapeutics (ORKA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed Celldex Therapeutics (CLDX) over the past year, gaining 286.5% versus a gain of 16.1%. Over five years, ORKA leads with a +137.5% price change compared with -34.1% for CLDX. Oruka Therapeutics is the larger company by market cap ($5.04 billion vs $2.27 billion), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDX | ORKA |
|---|---|---|
| Share price | $28.86 | $76.17 |
| Market cap | $2.27B | $5.04B |
| 1-day change | -5.16% | -4.18% |
| YTD return | +12.04% | +162.29% |
| 1-year return | +16.06% | +286.49% |
| 5-year return | -34.11% | +137.46% |
| EPS (TTM) | $-4.35 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54M | — |
| Revenue growth (YoY) | -77.99% | — |
| Net income (latest FY) | $-258.76M | $-105.43M |
| Gross margin | 87.06% | — |
| Operating margin | -18599.81% | — |
| Net margin | -16748.03% | — |
| 52-week high | $45.14 | $115.52 |
| 52-week low | $22.10 | $21.66 |
| Distance from 52-week high | -36.07% | -34.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +118.54% | +103.49% |
| Average volume | 1.27M | 886.21K |
| Shares outstanding | 78.53M | 66.21M |
| Employees | 198 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oruka Therapeutics is about 2.2 times larger than Celldex Therapeutics by market value ($5.04B vs $2.27B).
- ORKA has outperformed CLDX by 270.4 percentage points over the past year.
About Celldex Therapeutics
CLDX stock →Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 198 employees
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
CLDX vs ORKA FAQ
Which is bigger, Celldex Therapeutics or Oruka Therapeutics?
Oruka Therapeutics (ORKA) is larger, with a market capitalization of $5.04B compared with $2.27B for Celldex Therapeutics (CLDX).
Which stock has performed better over the past year, CLDX or ORKA?
ORKA returned +286.49% over the past 12 months, compared with +16.06% for CLDX (price return, excluding dividends). Past performance does not predict future results.
Are Celldex Therapeutics and Oruka Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.